Key Drivers
- Strong Cash Buffer
- Persistent Cash Burn
- Equity Dilution
AIAI Summary
PHVS is now a clinically de-risked but commercially unproven oral HAE franchise: CHAPTER-3's 83% attack reduction creates meaningful upside into 2027 FDA and filing catalysts, but investors should require evidence of approval, payer access, and adoption before underwriting sustained value given ongoing cash burn and dilution risk.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Cash Buffer
- •Persistent Cash Burn
- •Equity Dilution
PHVS offers strong cash liquidity and low leverage, but its high cash burn, absent revenue, recurring losses, and equity-driven dilution make it a high-risk, commercialization-dependent investment.
Price Behavior
Key Price Behavior Insights:
- •Volatile consolidation
- •Weakening momentum
- •Key breakout level
PHVS was volatile but directionless last month; holding above $35.30 is key, while a break above $38.90 would restore bullish momentum.
Sharp pullback to $36.37 after reaching $38.86 signals elevated volatility
Sentiment & News
Key News Insights:
- •Phase 3 success
- •83% attack reduction
- •Mixed investor flows
Pharvaris' strong Phase 3 CHAPTER-3 results and planned 2027 filings bolster its growth outlook despite mixed institutional and insider trading activity.
The positive clinical readout is a major catalyst for PHVS, though investor-positioning signals warrant monitoring
Similar Companies in Healthcare
Other companies in the same sector with AI ratings